[go: up one dir, main page]

WO2007047596A1 - Méthode de réduction de l'absorption d'aliments et de diminution de l'appétit chez les animaux - Google Patents

Méthode de réduction de l'absorption d'aliments et de diminution de l'appétit chez les animaux Download PDF

Info

Publication number
WO2007047596A1
WO2007047596A1 PCT/US2006/040408 US2006040408W WO2007047596A1 WO 2007047596 A1 WO2007047596 A1 WO 2007047596A1 US 2006040408 W US2006040408 W US 2006040408W WO 2007047596 A1 WO2007047596 A1 WO 2007047596A1
Authority
WO
WIPO (PCT)
Prior art keywords
animal
supplement
oleate
food
feeding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/040408
Other languages
English (en)
Inventor
Cheryl Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hills Pet Nutrition Inc
Original Assignee
Hills Pet Nutrition Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hills Pet Nutrition Inc filed Critical Hills Pet Nutrition Inc
Publication of WO2007047596A1 publication Critical patent/WO2007047596A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the invention relates generally to methods and compositions for modulating food intake and appetite in animals and particularly to the use of oleate compounds to modulate food intake and appetite in animals.
  • Fats are an important component of any diet as they provide energy, serve structural functions at the cellular level, act as carriers for fat soluble vitamins, and supply the essential fatty acids that are not adequately synthesized by particular animal species. Dietary fats generally improve palatability and provide an acceptable texture to foods. [0004] Dietary fats, however, have received a bad reputation in the recent past for contributing to obesity in humans and non-human animals, including companion animals such as cats and dogs.
  • Companion animals considered overweight and/or obese are increasing in number such that it is now estimated that in the U.S., between 25% and 40% of companion animals are considered overweight or obese.
  • An animal is considered overweight if it weighs more than 10% above its ideal body weight, and obese if it weighs more than 15% above its ideal body weight.
  • a companion animal has an ideal body weight if the animal's ribs can be felt, but not seen.
  • Obesity in companion animals is implicated in increased risk of diabetes mellitus, arthritis, pancreatitis, hepatic lipidosis, orthopedic disorders, cardiovascular disease, respiratory ailments, hip dysplasia, liver disease, gastrointestinal disorders, and skin problems.
  • Pets like humans, have been barraged with dieting schemes and exercise regimens to aid in controlling body weight. Advances have been made in development of reduced calorie pet foods, low-fat pet foods, increased non-soluble fiber pet foods, low carbohydrate/high protein pet foods and other pet foods marketed for weight control. Still, the statistics indicate that as a whole, opportunities for improvement remain and further advances in the art are needed.
  • Gastrointestinal disorders can be associated with obesity and include without limitation gastritis, inflammatory bowel disease, colitis, scours, and diarrhea. Such disorders can be painful, can cause mild to severe dehydration, and can ultimately result in hospitalization and/or death of the animal.
  • Various drugs are available to treat such conditions; however such drugs often require prescriptions and/or can have undesirable side effects.
  • the invention provides methods of reducing food intake in animals by feeding the animals a food supplement comprising a food intake reducing amount of at least one oleate compound prior to a meal.
  • the invention also provides methods for decreasing appetite in animals by feeding the animals a food supplement comprising an appetite decreasing amount of at least one oleate compound.
  • the invention further provides food supplements comprising, per serving thereof, one to a plurality of treats that comprise at least one oleate compound in a total amount per serving effective, upon feeding the supplement to an animal, to reduce food intake, decrease appetite, inhibit weight gain, and/or prevent or treat an obesity-related gastrointestinal disorder in the animal.
  • the invention also provides methods for inhibiting weight gain in an animal by feeding to the animal a food supplement within about 12 hours prior to mealtimes.
  • the supplement comprises, per serving thereof, one to a plurality of treats that comprise at least one oleate compound in a total amount per serving effective to inhibit weight gain in the animal.
  • the invention further provides methods for controlling weight of an animal by providing a nutritional regimen comprising (a) feeding to the animal a food supplement comprising a weight controlling effective amount of at least one oleate compound within about 12 hours prior to mealtimes and (b) feeding the animal at mealtimes a low fat food.
  • the invention also provides methods for preventing or treating a gastrointestinal disorder in an animal by feeding to the animal a food supplement comprising a gastrointestinal disorder preventing or treating effective amount of at least one oleate compound.
  • the invention further provides articles of manufacture comprising (a) a package containing a food supplement that comprises at least one oleate compound; and (b) a means for communicating information about or instructions for feeding the supplement to an animal to reduce food intake, decrease appetite, inhibit weight gain, and/or prevent or treat an obesity-related gastrointestinal disorder in the animal, said communicating means being attached to or enclosed in the package.
  • kits comprising (a) a package containing a food supplement comprising at least one oleate compound; and (b) a means for communicating information about or instructions for feeding the supplement to an animal to reduce food intake, decrease appetite, inhibit weight gain, and/or prevent or treat an obesity-related gastrointestinal disorder in the animal.
  • the invention further provides means for communicating information about or instructions for feeding a food supplement comprising at least one oleate compound to an animal to reduce food intake, decrease appetite, inhibit weight gain, and/or prevent or treat an obesity-related gastrointestinal disorder in the animal, the means comprising a label, a brochure, an advertisement, a package insert, a computer-readable digital or optical medium, an audio presentation, a visual presentation, or one or more pages on a website, containing the information or instructions.
  • the present invention provides methods for reducing food intake and decreasing appetite in animals; food supplements for reducing food intake and decreasing appetite in animals; methods for controlling weight in animals; and methods and food supplements for treating gastrointestinal disorders in animals.
  • oleate compound means non-glyceryl and non-amide derivatives of oleic acid, including but not limited to the free acid form, salts, non-glyceryl esters, other derivatives known in the art, and mixtures thereof.
  • the oleate compound is selected from the group consisting of oleic acid, ethyl oleate, sodium oleate, and mixtures thereof.
  • the oleate compound is oleic acid.
  • Oleic acid is an 18- carbon monounsaturated fatty acid (c/s-C18:l ⁇ -9), and the major monounsaturated fatty acid in human diets.
  • Plant sources of oleate compounds include, but are not limited to, high oleic peanuts, high oleic sunflower seeds, soybeans, almonds, olives, avocados, rapeseed, flax seed, cottonseed, coconut, linseed, palm, cocoa butter, corn, canola, and oils derived from these plant sources.
  • Animal sources of oleate compounds include, but are not limited to, chicken fat and lard.
  • the methods of the invention comprise feeding to an animal a food supplement comprising at least one oleate compound.
  • the supplement contains the oleate compound in an amount of from about 35% to about 100% of total crude fat, or in an amount of from about 5% to about 20% of the supplement on a dry matter basis.
  • a food supplement according to various other embodiments comprise at least one oleate compound in an amount of at least about 35% of total crude fat, or in an amount of from about 5% to about 20% of the supplement on a dry matter basis.
  • the phrase "reducing food intake" with respect to a factor external to an animal means a reduction in the amount of food consumed, relative to the amount of food consumed by the animal in the absence of that factor.
  • a food intake reducing amount of an oleate compound is an amount of the oleate compound that, when consumed by an animal, causes the animal to reduce the amount of food consumed.
  • the phrase "decreasing appetite" with respect to a factor external to an animal means a decrease in the animal's appetite, relative to the animal's appetite in the absence of that factor.
  • An appetite decreasing amount of an oleate compound is an amount of the oleate compound that, when consumed by an animal, causes the animal's appetite to decrease.
  • Gastrointestinal disorders include but are not limited to gastritis, inflammatory bowel disease, colitis, scours, diarrhea, and any other gastrointestinal disorder known in the art.
  • food supplements as used herein include, for example, a food used with another feed to improve nutritive balance or performance of the total. Supplements include compositions that are fed undiluted as a supplement to other feeds or offered free choice with other parts of an animal's ration and separately available. Food supplements may be in various forms including, for example, treats, kibbles, powders, liquids, syrups, pills, encapsulated compositions, etc. In a particular embodiment, a food supplement useful herein comprises one to a plurality of treats.
  • the invention provides methods for reducing food intake by an animal.
  • the method comprises feeding to the animal a food supplement comprising a food intake reducing amount of at least one oleate compound.
  • the invention provides a method for decreasing appetite in an animal.
  • the method comprises feeding to the animal a food supplement comprising an appetite decreasing amount of at least one oleate compound.
  • the invention provides a method for inhibiting weight gain in an animal comprising feeding to the animal a food supplement within about 12 hours prior to mealtimes.
  • the supplement comprises, per serving thereof, one to a plurality of treats that comprise at least one oleate compound in a total amount per serving effective to inhibit weight gain in an animal.
  • the supplement is fed to the animal within about 3 hours, or within about 1 hour, or immediately prior to mealtimes.
  • the invention provides a method for controlling weight in an animal.
  • the method comprises providing a nutritional regimen that comprises
  • the nutritional regimen should be maintained for a weight controlling effective period, for example, for at least about one month, illustratively for at least about 6 months, for at least about 1 year, or for substantially the remainder of an animal's life.
  • a method for preventing or treating a gastrointestinal disorder in an animal comprises feeding to the animal a food supplement comprising a gastrointestinal disorder preventing or treating effective amount of at least one oleate compound.
  • the invention provides a food supplement comprising, per serving thereof, one to a plurality of treats that comprise at least one oleate compound in a total amount per serving effective, upon feeding the supplement to an animal, to reduce food intake, decrease appetite, inhibit weight gain, and/or prevent or treat an obesity-related gastrointestinal disorder.
  • the treats are nutritionally and/or organoleptically adapted for feeding to canines or felines.
  • Treats as used herein include, for example, compositions that are given to an animal to eat during a non-mealtime. Treats are advantageous over pills as treats are a simpler method of causing an animal to ingest a desired substance. For example, treats are typically consumed voluntarily by an animal, while pills often need to be compulsorily administered. Treats include, without limitation, dog bones, dog biscuits, cat treats, etc.
  • Nutritional treats contain one or more nutrients in addition to the at least one oleate compound. Alternatively, a treat may contain substantially no nutrient other than the at least one oleate compound.
  • the components are adjusted so that the oleate compound is present in the supplement at a desired percentage.
  • the oleate compound can be present in a supplement in an amount of from about 35% to about 100% total crude fat, or in an amount of from about 5% to about 20% of the supplement on a dry matter basis.
  • the oleate compound can, for example, be incorporated into the supplement during formulation or coated onto the supplement.
  • An oleate compound can, if desired, be present in the supplement in encapsulated form.
  • an oleate comprising food supplement as described herein may further comprise one or more antioxidants and/or one or more polyunsaturated fatty acids.
  • the one or more polyunsaturated fatty acids can comprise, for example, an omega-3 fatty acid such as docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA).
  • DHA docosahexaenoic acid
  • EPA eicosapentaenoic acid
  • the methods, compositions, and supplements of the present invention are useful to a variety of animal species, including human and non-human animals such as non- human primates ⁇ e.g., monkeys, chimpanzees, etc.), companion animals (e.g., dogs, cats, horses, etc.), farm animals (e.g., goats, sheep, pigs, cattle, etc.), laboratory animals (e.g., mice, rats, etc.), birds (e.g., domestic birds such as canaries, parrots, etc.
  • human and non-human animals such as non- human primates ⁇ e.g., monkeys, chimpanzees, etc.
  • companion animals e.g., dogs, cats, horses, etc.
  • farm animals e.g., goats, sheep, pigs, cattle, etc.
  • laboratory animals e.g., mice, rats, etc.
  • birds e.g., domestic birds such as canaries, parrots, etc.
  • the animal is a vertebrate, for example a fish, a bird, a reptile, or a mammal.
  • the animal can be a member of the order Carnivora, including without limitation canine and feline species.
  • the invention is useful for animals of any age, breed, and occupation, including adult animals, senior animals, geriatric animals, overweight animals, obese animals, animals having a tendency toward obesity, and animals with gastrointestinal disorders.
  • the animal is a companion animal.
  • a "companion animal” herein is an individual animal of any species kept by a human caregiver as a pet, or any individual animal of a variety of species that have been widely domesticated as pets, including dogs ⁇ Canis familiaris) and cats ⁇ Felis domesticus), whether or not the individual animal is kept solely or partly for companionship.
  • "companion animals” herein include working dogs, farm cats kept for rodent control, etc., as well as pet dogs and cats.
  • the invention provides an article of manufacture comprising a package containing a food supplement that comprises at least one oleate compound.
  • a package containing a food supplement that comprises at least one oleate compound.
  • Any form of package appropriate to the nature of the composition can be used, including without limitation, a can, a jar, a pouch, a bag, a bag in a box, etc.
  • the article of this embodiment further comprises a means for communicating information about or instructions for administering the composition to an animal to reduce food intake, decrease appetite, inhibit weight gain, or prevent or treat an obesity-related gastrointestinal disorder in the animal.
  • the communicating means is attached to or enclosed in the package.
  • a kit comprises a package as described above containing a food supplement that comprises at least one oleate compound.
  • the kit of this embodiment further comprises a communicating means as described above.
  • the communicating means can be provided together with or separately from the package, and can take any suitable form, such as those described above including one or more pages on a website.
  • Such a communicating means comprising, for example, a document such as a label, brochure, advertisement or package insert, a computer readable digital or optical medium such as a diskette or CD, an audio presentation, for example on an audiotape or CD, a visual presentation, for example on a videotape or DVD, and/or one or more pages on a website, is itself a still further embodiment of the invention.
  • Dogs were maintained on a low fat diet and given a treat containing oleic acid prior to their daily meal. After an adjustment period, the dogs consuming the high oleic acid treat voluntarily consumed less food than the dogs fed a treat not containing oleic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet une méthode de réduction de l'absorption d'aliments pour animaux, de diminution de l'appétit, d'inhibition de la prise de poids et de traitement de troubles gastro-intestinaux. La méthode implique l'administration à un animal, préférentiellement un animal de compagnie, d'un composé de type oléate tel que l'acide oléique ou l'oléate d'éthyle. Le composé peut être administré sous forme d'une collation ou d'une friandise dans les 12 heures précédant les repas.
PCT/US2006/040408 2005-10-17 2006-10-17 Méthode de réduction de l'absorption d'aliments et de diminution de l'appétit chez les animaux Ceased WO2007047596A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72736505P 2005-10-17 2005-10-17
US60/727,365 2005-10-17

Publications (1)

Publication Number Publication Date
WO2007047596A1 true WO2007047596A1 (fr) 2007-04-26

Family

ID=37562129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040408 Ceased WO2007047596A1 (fr) 2005-10-17 2006-10-17 Méthode de réduction de l'absorption d'aliments et de diminution de l'appétit chez les animaux

Country Status (1)

Country Link
WO (1) WO2007047596A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013132092A1 (fr) * 2012-03-09 2013-09-12 Pensieve International Plc Utilisation de composés d'acides gras monoinsaturés pour contrôler le poids corporel d'un chien ou d'un chat

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723130A (en) * 1971-12-21 1973-03-27 J Stephenson Food additive composition of squalene,oleyl alcohol and oleic and linoleic acid
CH636013A5 (en) * 1978-03-07 1983-05-13 Sandoz Ag More readily absorbable pharmaceutical composition
WO2002000042A2 (fr) * 2000-06-26 2002-01-03 The Procter & Gamble Company Compositions et procedes de regulation du poids corporel
WO2004021799A1 (fr) * 2002-09-04 2004-03-18 The Iams Company Procédés et compositions de régulation pondérale

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723130A (en) * 1971-12-21 1973-03-27 J Stephenson Food additive composition of squalene,oleyl alcohol and oleic and linoleic acid
CH636013A5 (en) * 1978-03-07 1983-05-13 Sandoz Ag More readily absorbable pharmaceutical composition
WO2002000042A2 (fr) * 2000-06-26 2002-01-03 The Procter & Gamble Company Compositions et procedes de regulation du poids corporel
EP1676488A2 (fr) * 2000-06-26 2006-07-05 The Procter and Gamble Company Compositions et procédés de régulation du poids corporel
WO2004021799A1 (fr) * 2002-09-04 2004-03-18 The Iams Company Procédés et compositions de régulation pondérale

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALFENAS, R.C.G., AND MATTES, R.D., OBESITY RESEARCH., vol. 11, no. 2, 2003, USBATON ROUGE, LA,, pages 183 - 187, XP002413641 *
FINLEY, J.W., LEVEILLE, G.A., KLEMANN, L.P., SOURBY, J.C., AYRES, P.H., AND APPLETON, S.: "Growth method for estimating the caloric availability of fats and oils.", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY., vol. 42, 1994, USAMERICAN CHEMICAL SOCIETY. WASHINGTON., pages 489 - 494, XP002413640 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013132092A1 (fr) * 2012-03-09 2013-09-12 Pensieve International Plc Utilisation de composés d'acides gras monoinsaturés pour contrôler le poids corporel d'un chien ou d'un chat

Similar Documents

Publication Publication Date Title
AU2007208138B2 (en) Methods for reducing food intake and controlling the weight of animals
AU2010201222B2 (en) Methods for enhancing the quality of life of a growing animal
CA2784197C (fr) Methodes permettant d'ameliorer la qualite de vie d'un animal age
AU2007347423B2 (en) Compositions and methods for preventing or treating obesity in animals
WO2003061705A1 (fr) Systeme de gestion du poids s'appliquant a des mammiferes obeses
AU2003205279A1 (en) Weight management system for obese animals
US20230189845A1 (en) Food compositions and methods for preventing copper-associated hepatopathies
Aldrich Rendered products in pet food
AU2012396850B2 (en) Anti-aging foods for companion animals
Lisboa et al. Feeding behavior of feedlot-finished crossbred bulls fed palm kernel cake
WO2007047596A1 (fr) Méthode de réduction de l'absorption d'aliments et de diminution de l'appétit chez les animaux
Oyarzun et al. An evaluation of the nutritional adequacy of the feeding program of the black-footed ferret (Mustela nigripes) at the Metropolitan Toronto Zoo
AU2012394450B2 (en) Hairball control through dietary mineral limitation
Mark dos Anjos How Much and How Often Should I Feed My Senior Cat?
Longland et al. 19 The Nutrition of Companion Animals

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06826048

Country of ref document: EP

Kind code of ref document: A1